Protagonist Therapeutics, Inc (PTGX) › Shareholders' EquityProtagonist Therapeutics, Inc (PTGX) — Shareholders' EquityAnnual figures by period end, from SEC filings.2013-12-31: -$1.39M2014-12-31: -$12.62M2015-12-31: -$27.40M2016-12-31: $87.56M2017-12-31: $120.63M2018-12-31: $112.52M2019-12-31: $79.96M2020-12-31: $279.61M2021-12-31: $300.02M2022-12-31: $215.61M2023-12-31: $336.68M2024-12-31: $675.29M2025-12-31: $614.71M$614.71M2013-12-31Shareholders' Equity (USD)2025-12-31Period endedShareholders' EquityChange YoYSource filing2025-12-31$614.71M-9.0%2026-02-25Balance as of period end2024-12-31$675.29M+100.6%2026-02-25Balance as of period end2023-12-31$336.68M+56.2%2026-02-25Balance as of period end2022-12-31$215.61M-28.1%2026-02-25Balance as of period end2021-12-31$300.02M+7.3%2025-02-21Balance as of period end2020-12-31$279.61M+249.7%2024-02-27Balance as of period end2019-12-31$79.96M-28.9%2023-03-15Balance as of period end2018-12-31$112.52M-6.7%2022-02-28Balance as of period end2017-12-31$120.63M+37.8%2021-03-10Balance as of period end2016-12-31$87.56M—2020-03-10Balance as of period end2015-12-31-$27.40M—2019-03-12Balance as of period end2014-12-31-$12.62M—2018-03-07Balance as of period end2013-12-31-$1.39M—2017-03-07Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)